Risankizumab Improves Skin, Joint Symptoms in Psoriatic Arthritis - Rheumatology Network

Patients with psoriatic arthritis receiving risankizumab reported improved joint and skin symptoms when compared with placebo.

Over the course of 16 weeks, patients with psoriatic arthritis (PsA) receiving risankizumab reported improved joint and skin symptoms when compared with placebo. Improvements were maintained long-ter… [+3807 chars]

full article...